Strategic partnerships Curida has a recent strategic partnership with Rommelag SE & Co. (Oct 2025) to enhance BFS technology capabilities, presenting a cross-selling opportunity to align customers needing BFS sterile fill processes with Rommelag’s capabilities and Curida’s CDMO services.

Green branding Eco initiatives have been recognized with an EcoVadis Bronze award in 2026, signaling strong sustainability credentials that can be leveraged to win business from sustainability-minded pharma clients and to differentiate in bids requiring environmental responsibility.

Global capacity fit Operating as a Nordic-based CDMO with experience serving both small biotech and Big Pharma, Curida offers flexible, scalable sterile and aseptic manufacturing with BFS and nasal spray core technologies, appealing to sponsors seeking reliable, adaptable manufacturing partners for diverse pipelines.

Growth funding Significant investment from Signet Healthcare Partners and other investors in 2024 indicates strong financial backing and growth potential, which can be used to reassure potential customers about stability and planned capacity expansion.

Market expansion Active participation in industry events (euroPLX engagement planned for March 2026) and a refreshed website launched in 2025 suggest momentum in market outreach and lead-generation activities that can be complemented with targeted outreach to pharma companies seeking CDMO partnerships for sterile manufacturing.